Diamond Biofund is the first publicly listed evergreen biotech venture capital firm in Taiwan. The founding shareholders include Microbio Group and financial conglomerates - Fubon Financial, Taishin Holdings, and Ruentex Group. With our mission to "Nurture Innovation for Better Quality of Life," Diamond Biofund specializes in biotechnology and medical investments, targeting globally competitive opportunities, including new drug R&D, high-end medical equipment, innovative medical services and channels, and agricultural biotechnology. Diamond Biofund has invested in more than 20 biotech startups in Taiwan and abroad. In addition to financial investment, Diamond Biofund provides invaluable support to portfolio companies in diverse areas, such as corporate governance, R&D, clinical implementation, business development, and capital market integration, all aimed at driving portfolio growth and delivering investment returns to shareholders.
With the vision of becoming a globally influential biotech venture capital, Diamond Biofund continues to:
Expand funding source from public and private capital markets
Invest globally to incubate world-class competitive biomedical companies
Transform cutting-edge innovation to fulfill unmet medical needs
Create investment value and establish a prestigious venture capital brand
Performance Review (2013-2023)
Over the past decade, founding shareholders have 17X return on their investment.
Created two biotech companies each with a market value exceeding US$1 billion.
Supported 6 top universities and research institutions, including Academia Sinica, National Taiwan University, National Tsing Hua University, Taipei Medical University, National Defense Medical Center, and National Chung Hsing University, leading to 7 successful innovative biotech startups, with 4 of them having already entered the capital market or been acquired.
Supported high-end talent cultivation and medical research with over US$20 million.
The first venture capital company listed on the Main Board of TWSE in Taiwan.
Action after listing
Position as an evergreen venture capital and expand investment size.
Initiate additional investment funds through connections with the capital market.
Support innovative research and development by leveraging biotech expertise.
Forge international mergers and acquisitions by developing international resources.
Transparent information disclosure
Daily announcement of the fair values of portfolio companies at TWSE, TPEx, and TPEx Emerging Board on our official website.
Monthly announcement of the changes in the numbers of shares held in the portfolio companies and the changes in their fair values, as well as the Company’s book value per share and cash and cash equivalent balances, on our official website and through MOPS’ material information.
Quarterly investor conference to report the financial and business status, as well as revenue recognition characteristics.
Timely announcement through MOPS’ material information to alert investors when the Company’s operating revenue remains negative for three consecutive months.
